Director, Economic & Predictive Modeling, GHEOR at Bristol-Myers Squibb

Uxbridge, England, United Kingdom

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

PharmaceuticalsIndustries

Requirements

Doctorate Degree (PhD) or Master’s (MSc) in health economics or related relevant discipline
10+ years of health economics and outcomes research experience
Experience using Visual Basic, and software including R, Python, OPEN BUGS and JAGS, ideally with the ability to program, interpret and modify existing code
Lead projects as the subject matter expert, providing strategic direction and expertise while overseeing execution and ensuring successful outcomes
Project management skills with ability to communicate effectively across all levels of the matrix
Successful development of model development for HTA submissions including adaptations for country needs
Innovative methods evidenced by published research
Experience in leading research and presenting at conferences as well as to internal matrix stakeholders

Responsibilities

Provide expert modelling, AI, and programming capabilities to GHEOR TA teams
Execute market level CE model adaptations using the Bristol Myers Squibb (BMS) GHEOR EPM Generative AI tool suite
Execute and present methods shaping innovative research, panels, publications, education, and external talks to shape the HTA and payer environment – primary focus on AI methods for access & HEOR
Develop innovative HTA methods that delivers rapid access for BMS medicines – specific focus on AI capabilities that increase speed to patient and reduced operating costs
Lead the BMS external strategy to evolve payer/HTA agency methodology in the assessment of the value of BMS Neuroscience and Immunology / Cardiovascular portfolio
Act as scientific leader for the latest modelling methodology that optimises the assessment of BMS Neuroscience and Immunology / Cardiovascular assets
Horizon scan latest advances in HTA methodology from academia, payers and competitors embedding key learnings
Partner with global asset leads and BMS affiliates to implement the AI based model adaptations program – work effectively with BMS internal EPM contractor team
Ability to hands on deliver structural updates to economic models
Provide expert level support in development of cost-effectiveness and budget impact models in collaboration with cross-functional local, regional and global teams
Provide early HEOR analytics to inform pricing strategies for CE archetypes as requested
Provide modelling input to Value Story development and updates
Interpret clinical studies results and plan additional statistical analyses needed for core models and model adaptations, including indirect treatment comparisons
Engage in timely and effective communication to HTA and reimbursement authorities as requested / required by matrix teams
Lead publications of core global economic models
Thought leadership on modelling internally and externally, to help shape the HTA business environment and standards
Highly competent matrix collaborator
Active membership within the Model Protocol Review Committee

Skills

Generative AI

HTA Modeling

Predictive Modeling

Economic Modeling

Programming

Cost-Effectiveness Modeling

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free